This image provided by Bristol Myers Squibb in October 2024 shows production of the company's drug Cobenfy, which the U.S. Food and Drug Administration approved for the treatment of schizophrenia in September 2024. (Bristol Myers Squibb via AP)
Photos
News Sections
In Other News
- U.S: Trump and Harris both support a bigger child tax credit. But which families should get it?
- World: Spain searches for bodies after unprecedented flooding claims at least 158 lives
- Politics: Kamala Harris says Trump's comment on women 'is offensive to everybody'
- Sports: World Series champion Dodgers have eye on back-to-back titles with Ohtani returning to mound in 2025
- Showbiz: ‘Dances with Wolves’ actor is again indicted on sexual abuse charges in Nevada
- Money: Apple sells $46 billion worth of iPhones over the summer as AI helps end slump
- Tech: Apple's iPhone sales bounce back from recent slump amid AI expansion, but stock still dips
- Science: A promising schizophrenia drug showed mixed results. What does that mean for patients?
- Health: 'Obamacare' enrollment opens, as Republicans threaten the health insurance program used by millions